Firma Kuros Biosciences, Autor bei PR-Web

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals

Posted on 15. July 202115. July 2021 by Firma Kuros Biosciences Posted in Research / Development Tagged bone, checkmate, fibrin, graft, kuros, magnetos, pth, revenue, royalties, royalty, statements, tlr9, vidutolimod, with, xoma

Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the […]

Kuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration

Posted on 22. June 202122. June 2021 by Firma Kuros Biosciences Posted in Research / Development Tagged bone, cells, cervical, clinical, ECM, graft, kuros, magnetos, patients, power, spinal, statements, sur, with, wound

. First peer-reviewed article with demonstrated efficacy in preclinical and clinical studies Outlines ability of MagnetOs to deliver uniform, stable and reliable bone fusions Kuros Biosciences (SIX: KURN) today announced the publication of new data in eCM Journal, a peer-reviewed […]

Kuros Biosciences to present at upcoming U.S. spine conferences

Posted on 17. June 2021 by Firma Kuros Biosciences Posted in Research / Development Tagged bone, cns, equiva, fibrin, gold, implant, kuros, magnetos, mountain, osseous, posterolateral, pth, statements, with, wound

Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that high-profile surgeons will present on the STRUCTURE clinical trial with Fibrin-PTH and on preclinical and clinical […]

Kuros to receive $4 million milestone payment from Checkmate Pharmaceuticals

Posted on 17. May 2021 by Firma Kuros Biosciences Posted in General Tagged bone, checkmate, dosing, financial, fur, graft, immunotherapies, kuros, patients, payment, royalties, statements, treatment, unresectable, with

. • Milestone triggered by Checkmate’s initiation of potential registration trial of vidutolimod (CMP-001) in patients with anti-PD-1 refractory advanced melanoma • Kuros stands to receive up to $49 million additional milestones plus royalties on sales Kuros Biosciences […]

Kuros Biosciences strengthens its patent position on use of Fibrin-PTH in spinal fusion

Posted on 5. May 2021 by Firma Kuros Biosciences Posted in General Tagged biosciences, bone, clinical, derivatives, fibrin, financial, graft, kuros, market, orthobiologics, patients, pth, spinal, statements, with

Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidiary, Kuros Biosurgery AG, has been granted European patent EP 2686027, entitled ‘Pharmaceutical Formulation for Use in Spinal Fusion’. This patent claims certain […]

Kuros Biosciences publishes invitation to the Annual General Meeting 2021

Posted on 29. March 2021 by Firma Kuros Biosciences Posted in General Tagged bone, cells, chf, clinical, dividend, fibrin, graft, kuros, magnetos, orthobiologics, pth, spinal, statements, with, wound

Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today published the invitation and agenda for its Annual General Meeting, to be held on April 19, 2021, 11.00 […]

Kuros Biosciences reports results for the full year 2020

Posted on 18. March 2021 by Firma Kuros Biosciences Posted in General Tagged bone, checkmate, chf, fibrin, gold, graft, kuros, magnetos, orthobiologics, patients, pth, revenues, statements, tlif, with

Financial highlights CHF 29.8 million cash & cash equivalents, trade and other receivables at December 31, 2020 Revenues increased by 58% to CHF 4.0 million Operational highlights Initiated Phase II clinical study of Fibrin-PTH in spine Commercial rollout in the […]

Kuros Biosciences to present at upcoming clinical and investor conferences

Posted on 10. March 2021 by Firma Kuros Biosciences Posted in Research / Development Tagged bone, cervical, extender, gold, implant, kuros, magnetos, market, osseous, patients, posterolateral, statements, vitoss, with, wound

Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that the company will present at two major European conferences in March, both to be held virtually. […]

Kuros Biosciences announces MagnetOs sales and distribution agreements across Northern Europe

Posted on 2. March 20214. March 2021 by Firma Kuros Biosciences Posted in General Tagged axis, bone, cells, clinical, gold, graft, implants, kuros, magnetos, orthobiologics, research, spinal, statements, with, wound

Agreements in Netherlands, Switzerland and Austria and letter of intent in Finland Supports further acceleration of sales of MagnetOs bone graft Kuros Biosciences (SIX: KURN) today announced that it has signed sales and distribution agreements for MagnetOs bone graft, covering […]

Kuros announces results of Rights Offering

Posted on 20. October 20204. March 2021 by Firma Kuros Biosciences Posted in Research / Development Tagged bone, chf, extender, fibrin, implant, kuros, magnetos, market, osseous, posterolateral, prospectus, pth, securities, statements, with

Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the results of its Rights Offering, first announced on October 5, 2020, in which a total of up to 8,426,229 newly registered shares of Kuros with a nominal value of CHF […]